



Contacts:

David Waldman or Justyna Gudaszewska
Crescendo Communications Europe
Email: mmd@crescendo-ir.com
Tel: (+48 71) 79 11 551

Milestone Milestone Inc. Announces Approval of its Prospectus, Planned Public Offering of its Common Stock and Uplisting to Main Market of Warsaw Stock Exchange later this year

Reaffirms Plans for Full Commercial Launch in the United States and Europe In 2016

LIVINGSTON, NJ, December 07, 2015 -- Milestone Medical Inc. (WAR: MMD) announced that it has received on Friday, December 4, 2015, an approval for its Prospectus by Polish Financial Supervision Authority to conduct the public offering of its common shares and admit the shares to trading on Main Market of the Warsaw Stock Exchange. Subscription of shares in the retail tranche are scheduled from December 8 to December 14, 2015 to be conducted by retail consortium of brokerage houses – Vestor Dom Maklerski S.A. and Biuro Maklerskie Alior Bank S.A. The Co-offering Agent is Graviton Capital S.A. Milestone Medical plans to raise \$10 million through a common stock offering of up to 3,200,000 shares. New shares issue will constitute up to 12.7% of all share capital post the offering. Following the offering, the company will uplist its shares from the New Connect market to Main Market of the Warsaw Stock Exchange later this year.

Leonard Osser, Chief Executive Officer of Milestone Medical, commented, “The approval of our Prospectus is an important development for the company and reflects our continued progress as we move forward with commercial launch of our medical instruments. The capital raised will be used for the continued expansion of our sales and marketing initiatives, as well as additional working capital to accelerate the full rollout of our epidural and intra-articular instruments in United States and Europe in 2016. We believe transitioning to the Main Market of Warsaw Stock Exchange will provide us the increased awareness within the investment community and improved liquidity as well as will expand the audience of potential investors in the Company.”

Mr. Osser continued, “We are now entering the final stage of U.S clinical trial that will be in labor and delivery to demonstrate the accuracy of our CompuFlo® technology in identifying and confirming the epidural space location as part of the US regulatory pathway. Upon successful completion of the clinical trial later this year and statistical analysis of the studies, we will return to the FDA for final marketing clearance for our epidural instrument.

Based on the initial outcomes of COMPASS clinical study for chronic pain management, we remain convinced that CompuFlo® technology has the potential to successfully replace the current standard of medical care. Our technology was as accurate and effective as the loss of resistance technique assisted with radiological X-ray based fluoroscopy in objectively and accurately identifying the epidural space, while eliminating the exposure to radiation.

Upon completion of the U.S. clinical trials, we look forward to launching an aggressive European roll-out strategy. Earlier this year, we signed our first agreements with distributors in Europe. We look forward to announcing next agreements in the near future. We are now introducing our instruments initially to key opinion leaders in Poland and other European markets, which provides important independent validation regarding the instrument’s efficacy.”

The U.S. epidural market is estimated at over \$7 billion annually and over 2.4 million women in the U.S. receive epidurals while in labor each year with another 1.6 million women who give birth choosing not to have an epidural, mainly due to safety concerns, which can include severe pain, wet tap paraplegia and death. In Europe, the addressable market for epidurals is estimated to be even larger than the U.S.

Public offering is scheduled for following dates:

To 07.12.2015 r.

Public Disclosure of maximum price

From 08.12.2015 r. to 15.12.2015 r.

Bookbuilding / roadshow

From 08.12.2015 r. to 14.12.2015 r.

Subscriptions and payments in the Retail Tranche

To 16.12.2015 r.

Public disclosure of the issue price, the final number of the shares offered and the final number of Shares Offered in each tranche

From 16.12.2015 r. to 17.12.2015 r.

Subscriptions and payments in the Institutional Tranche

To 22.12.2015 r.

Allocation of shares in Retail Tranche through WSE

To 22.12.2015 r.

Allocation of shares in Institutional Tranche

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing regulatory approval for both instruments in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit www.medicalmilestone.com.

Safe Harbor Statement

This press release is for informational and promotional purposes only and does not constitute an offer to subscribe for or buy the securities of Milestone Medical ("the Company"). The Prospectus is the only legally binding offering document containing, for the purpose of the offering, admission and introducing to the trading on regulated market maintained by the Warsaw Stock Exchange in Warsaw of the Company's securities. The Prospectus was published and is available in an electronic form on the Company's website (www.medicalmilestone.com) as well as on the website of the Offering Agent – Vestor Dom Maklerski S.A. (www.vestor.pl). This document is not to be published, distributed or disseminated to persons resident or physically present in the United States, Canada, Australia and Japan.